摘要
<strong>Introduction</strong><span><span><span style="font-family:;" "=""><strong>:</strong> The treatment of viral hepatitis B is based on nucleotide analogs(s). In Burkina Faso, tenofovir is the most widely used because of its effectiveness and cost. The aim of this study was to describe viral hepatitis B under tenofovir in Ouagadougou. <b>Material and Method</b>: This was a longitudinal study, carried out in the outpatient department of the University Hospital of Tengandogo from May 1, 2013 to September 31, 2020, <i>i.e.</i> a period of seven (07) years and five (05) months. All patients with chronic hepatitis B virus who had been taking tenofovir for at least one year were included in the study. Cases of hepatocellular carcinoma and co-infections with hepatitis D, C and human immunodeficiency viruses were excluded from the study. <b>Results</b>: Of 321 patients with hepatitis B, 120 were on tenofovir and 34 were included in our study. These were 24 men and 10 women with an average age of 39 years. Hepatitis B was most often discovered following systematic or voluntary screening (44.1%) or pain in the right hypochondrium (23.5%). The mean initial viral load was 7.9</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span><span><span style="font-family:;" "="">log. Ten patients had moderate compliance and four were non-compliant. No side effects were reported in 91.3% of cases. The virologic response was complete in 72.7% of patients after six months. Nine out of ten patients showed a biochemical response after 16 months. A histological response was observed in 19/27 patients within a mean of 26.7 months. HBs seroconversion was found in 2/24 patients. <b>Conclusion</b>: Tenofovir is effective in the treatment of viral hepatitis B, but HBs seroconversion is rarely achieved.</span></span></span>
<strong>Introduction</strong><span><span><span style="font-family:;" "=""><strong>:</strong> The treatment of viral hepatitis B is based on nucleotide analogs(s). In Burkina Faso, tenofovir is the most widely used because of its effectiveness and cost. The aim of this study was to describe viral hepatitis B under tenofovir in Ouagadougou. <b>Material and Method</b>: This was a longitudinal study, carried out in the outpatient department of the University Hospital of Tengandogo from May 1, 2013 to September 31, 2020, <i>i.e.</i> a period of seven (07) years and five (05) months. All patients with chronic hepatitis B virus who had been taking tenofovir for at least one year were included in the study. Cases of hepatocellular carcinoma and co-infections with hepatitis D, C and human immunodeficiency viruses were excluded from the study. <b>Results</b>: Of 321 patients with hepatitis B, 120 were on tenofovir and 34 were included in our study. These were 24 men and 10 women with an average age of 39 years. Hepatitis B was most often discovered following systematic or voluntary screening (44.1%) or pain in the right hypochondrium (23.5%). The mean initial viral load was 7.9</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span><span><span style="font-family:;" "="">log. Ten patients had moderate compliance and four were non-compliant. No side effects were reported in 91.3% of cases. The virologic response was complete in 72.7% of patients after six months. Nine out of ten patients showed a biochemical response after 16 months. A histological response was observed in 19/27 patients within a mean of 26.7 months. HBs seroconversion was found in 2/24 patients. <b>Conclusion</b>: Tenofovir is effective in the treatment of viral hepatitis B, but HBs seroconversion is rarely achieved.</span></span></span>
作者
Soudré Sandrine Marie-Odile Bobilwindé
Napon Fahosiata
Zoungrana Steve Léonce
Ouattara Zanga Damien
Koura Mali
Guingané Nanelin Alice
Somda Sosthène
Coulibaly Aboubacar
Beni Da Nathalie
Salou Rodrigue
Bougouma Alain
Sombié Arsène Roger
Soudré Sandrine Marie-Odile Bobilwindé;Napon Fahosiata;Zoungrana Steve Léonce;Ouattara Zanga Damien;Koura Mali;Guingané Nanelin Alice;Somda Sosthène;Coulibaly Aboubacar;Beni Da Nathalie;Salou Rodrigue;Bougouma Alain;Sombié Arsène Roger(Hepato-Gastroenterology Unit of the University Hospital Tengandogo, Burkina Faso, Africa;Hepato-Gastroenterology Unit of the University Hospital Ouahigouya, Burkina Faso, Africa;Gastroenterology Service of the University Hospital Souro Sanou, Bobo-Dioulasso, Burkina Faso, Africa;Gastroenterology Service of the University Hospital Bogodogo, Ouagadougou, Burkina Faso, Africa;Gastroenterology Service of the University Hospital Yalgado Ouédraogo, Ouagadougou, Burkina Faso, Africa)